<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784757</url>
  </required_header>
  <id_info>
    <org_study_id>3104003</org_study_id>
    <secondary_id>2012-002279-32</secondary_id>
    <nct_id>NCT01784757</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer</brief_title>
  <acronym>ARAFOR</acronym>
  <official_title>A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate which of two different tablet formulations of ODM-201 is best suited&#xD;
      for use in the further development of the compound in the treatment of metastatic&#xD;
      chemotherapy-naive castration-resistant prostate cancer. Patients successfully completing the&#xD;
      bioavailability study will be able to receive further treatment with the current capsule&#xD;
      formulation of ODM-201 until progression of their disease with the safety and tolerability of&#xD;
      ODM-201 being assessed throughout.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of ODM-201</measure>
    <time_frame>0-48 hrs</time_frame>
    <description>The area under the concentration-time curve from time zero to the last sample with the quantifiable concentration calculated with linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of ODM-201</measure>
    <time_frame>0-48 hrs</time_frame>
    <description>The plasma peak concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of ODM-201</measure>
    <time_frame>0-48 hrs</time_frame>
    <description>The time to reach peak concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant of ODM-201</measure>
    <time_frame>0-48 hrs</time_frame>
    <description>The terminal elimination rate constant from log-linear portion of a concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life of ODM-201</measure>
    <time_frame>0-48 hrs</time_frame>
    <description>The terminal elimination half-life that will be calculated with the equation ln2/terminal elimination rate constant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ODM-201 Tablet A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-201 Tablet B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201 Tablet A</intervention_name>
    <description>Tablet A formulation of ODM-201</description>
    <arm_group_label>ODM-201 Tablet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201 Tablet B</intervention_name>
    <description>Tablet B formulation of ODM-201</description>
    <arm_group_label>ODM-201 Tablet B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201 capsule formulation</intervention_name>
    <description>Capsule formulation of ODM-201</description>
    <arm_group_label>ODM-201 Tablet A</arm_group_label>
    <arm_group_label>ODM-201 Tablet B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of prostate&#xD;
&#xD;
          -  Progressive metastatic disease&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone&#xD;
             (LHRH) analogue or antagonist or bilateral orchiectomy&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function&#xD;
&#xD;
          -  Able to swallow the ODM-201 whole as a capsule or tablet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for prostate cancer.&#xD;
&#xD;
          -  Known metastases in the brain.&#xD;
&#xD;
          -  History of other malignancy within the previous 5 years, except a basal cell carcinoma&#xD;
             of skin.&#xD;
&#xD;
          -  Known gastrointestinal condition that can significantly affect the absorption of the&#xD;
             study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Fizazi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, University of Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P. Stradina Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

